Perioperative durvalumab with enfortumab vedotin given only before cystectomy cut the risk of an EFS event by 49% in the phase 3 VOLGA trial.
News|Articles|August 12, 2026
Tudriqev Melanoma Approval: Essential Oncolytic Guide for Oncology Nurses
Author(s)By ONN Staff
Fact checked by: Alex Biese
FDA approves Tudriqev-nivolumab for advanced melanoma. Learn key clinical trial data, dosing math, and safety rules for oncology nursing teams.
Advertisement
Advertisement
The US Food and Drug Administration (FDA) has granted accelerated approval to vusolimogene oderparepvec-wtpg (Tudriqev; Replimune, Inc.), a genetically modified oncolytic viral therapy, in combination with nivolumab. This novel regimen is indicated for adult patients with unresectable advanced cutaneous melanoma who experienced disease progression on a prior programmed death receptor-1 (PD-1)-blocking antibody-based regimen.
Related to this article
The PCR-based tissue assay can now identify patients with MSI-high solid tumors who may be candidates for pembrolizumab.
The oral CSF-1R inhibitor produced a 54% response rate vs 3% with placebo at week 25 in the phase 3 MANEUVER trial.
FDA grants accelerated approval to amivantamab and hyaluronidase-lpuj for recurrent or metastatic head and neck squamous cell carcinoma.
A 3-minute video and quick-reference list of October's 7 FDA cancer approvals, with the biomarker and monitoring points nurses need for each.
At an Oncology Nursing News roundtable, APPs discussed earlier lifileucel referral, IL-2 dosing, and toxicities that emerge after discharge.
Modeling projects anthracycline recipients may lose a median 9.4 life-years to age acceleration, a finding with survivorship care implications.
Oncology NPs and PAs are key to closing workforce gaps. Here’s how generalist, specialist, and hybrid APP models improve access and outcomes.
Advertisement
Advertisement